CAPR Capricor Therapeutics Inc.

+0.14  (7%)
Previous Close 2.00
Open 2.08
Price To book -7.64
Market Cap 50281973
Shares 23,496,249
Volume 1,853,562
Short Ratio 2.33
Av. Daily Volume 2,620,494

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 completed. Waiting on data from additional study to determine future
Ambulatory heart failure
Phase 1/2 6-month data to be presented October 6, 2017.
CAP-1002 HOPE-Duchenne
Duchenne Muscular Dystrophy (DMD)
Phase 2 data released May 12, 2017 - primary endpoint unlikely to be met.
Myocardial infarction (heart attack)

Latest News

  1. ETFs with exposure to Capricor Therapeutics, Inc. : September 22, 2017
  2. Capricor Therapeutics, Inc. :CAPR-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017
  3. Today's Research Reports on Stocks to Watch: Capricor Therapeutics and Supernus Pharmaceuticals
  4. Capricor Therapeutics to Present Six-Month Results from the Randomized HOPE Trial of CAP-1002 in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society
  5. ETFs with exposure to Capricor Therapeutics, Inc. : August 11, 2017
  6. Capricor reports 2Q loss
  7. Capricor Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
  8. Investor Network: Capricor Therapeutics, Inc. to Host Earnings Call
  9. 10 Pieces Of Advice Every Penny Stock Trader Should Know
  10. Capricor Therapeutics Second Quarter 2017 Update Webcast and Conference Call Scheduled for Thursday, August 10
  11. We Spoke With The Experts, And Learned The Secrets Behind Beating The Penny Stock Market
  12. Capricor Announces Results of FDA Meeting on Intravenous CAP-1002 for Duchenne Muscular Dystrophy
  13. Rodman and Renshaw Sings the Praises of Capricor Therapeutics, Inc. (CAPR); Here’s Why
  14. Today's Research Reports on Stocks to Watch: Capricor Therapeutics and Immunocellular Therapeutics
  15. Tuesday’s Wall Street News: Netflix, Inc. (NFLX), Capricor Therapeutics Inc (CAPR), Moleculin Biotech Inc (MBRX)
  16. Capricor Receives Rare Pediatric Disease Designation from FDA for CAP-1002 for Patients with Duchenne Muscular Dystrophy
  17. Featured Company News - Janssen Biotech Backs Out of Exclusive Licence Agreement for Development and Commercialization of Capricor's Lead Candidate CAP-1002
  18. Capricor Therapeutics Retains Full Rights to CAP-1002 as Janssen Biotech, Inc. Decides Not to Exercise Option
  19. Six-Month Results from Capricor's HOPE-Duchenne Trial to be Presented at the 2017 PPMD Annual Connect Conference

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171030243
  2. 8-K - Current report 171021486
  3. EFFECT - Notice of Effectiveness 17968445
  4. 424B3 - Prospectus [Rule 424(b)(3)] 17968142
  5. S-3 - Registration statement under Securities Act of 1933 17953717
  6. 8-K - Current report 17953521
  7. 8-K - Current report 17945739
  8. 8-K - Current report 17919797
  9. 8-K - Current report 17907940
  10. 8-K - Current report 17895084